Arbutus Biopharma Corporation
ABUS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6 | $18 | $39 | $11 |
| % Growth | -66% | -53.5% | 255.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $6 | $18 | $39 | $11 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $54 | $74 | $84 | $66 |
| G&A Expenses | $22 | $22 | $18 | $17 |
| SG&A Expenses | $22 | $22 | $18 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $6 | $0 | $2 | $2 |
| Operating Expenses | $82 | $96 | $104 | $85 |
| Operating Income | -$76 | -$78 | -$65 | -$74 |
| % Margin | -1,236.7% | -430.5% | -167.8% | -669.1% |
| Other Income/Exp. Net | $6 | $5 | $0 | -$3 |
| Pre-Tax Income | -$70 | -$73 | -$65 | -$76 |
| Tax Expense | $0 | $0 | $4 | $0 |
| Net Income | -$70 | -$73 | -$69 | -$76 |
| % Margin | -1,133% | -401.6% | -178% | -693.9% |
| EPS | -0.38 | -0.44 | -0.46 | -0.73 |
| % Growth | 13.6% | 4.3% | 37% | – |
| EPS Diluted | -0.38 | -0.44 | -0.46 | -0.73 |
| Weighted Avg Shares Out | 186 | 166 | 151 | 106 |
| Weighted Avg Shares Out Dil | 186 | 166 | 151 | 106 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $6 | $2 | $0 |
| Interest Expense | $0 | $0 | $2 | $3 |
| Depreciation & Amortization | $1 | $1 | $1 | $2 |
| EBITDA | -$68 | -$71 | -$62 | -$72 |
| % Margin | -1,108.5% | -391.3% | -158.5% | -652% |